An accompanying research for the Phase II study of nivolumab + bevacizumab + paclitaxel in patients with HER2-negative metastatic breast cancer:WJOG9917B(WJOG9917BTR)
Not Applicable
- Conditions
- HER2-negative metastatic breast cancer
- Registration Number
- JPRN-UMIN000029590
- Lead Sponsor
- West Japan Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 51
Inclusion Criteria
Not provided
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Immune-related biomarker of nivolumab in combination with paclitaxel and bevacizumab
- Secondary Outcome Measures
Name Time Method